Matthias Müllenbeck: What if we paid doctors to keep people healthy?
As the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Full bio
Double-click the English transcript below to play the video.
fell off the evening before.
I'm sitting in a dentist's chair.
so that I can get rid of my pain,
of a titanium implant surgery.
a damaged tooth
may add up to 10,000 US dollars.
that could be earned with me
for my dentist?
wasn't an isolated case.
estimated that in the United States,
surgical procedures --
and pacemaker implantations,
options had not been fully exploited
in other countries,
if you go to a doctor in the US,
to be subjected to a surgical intervention
an immediate need for it.
to run such unnecessary procedures?
health care systems themselves
certain procedures or treatments.
reimburse practitioners
of treatments performed,
that tempts some practitioners
surgical treatments
other treatment options.
started to implement
health care systems' architecture
of a disease in the first place
applied to a patient
system's architecture --
of the incentive structure.
for keeping their customers healthy
once people are already sick.
that largely cares for the sick,
people once they have become sick
before they get sick.
of all those involved --
to pharmaceutical and medical companies --
ultimately sells:
reimburse practitioners
performed on a patient
individual is kept healthy
to an insurance company
is kept healthy
of acute medical intervention.
any further monetary compensation
to treat the disease of that individual,
for every evidence-based treatment option
will be paid again.
their customers healthy,
any unnecessary medical interventions
that eventually become sick.
to treat the sick will be,
for all parties being involved
structure shifts, now,
health care system
and singular treatment options,
to stay healthy and live long.
to share their health data
understands early enough
to their health is needed.
cardiometabolic profiling
and general practitioners,
and their physical activity --
individual high-risk disease.
data analysis
of sensor technologies
of the individual health status possible.
by devices like this
tumor DNA in your bloodstream
for such monitoring technologies.
in certain oncological diseases
is diagnosed too late
that could potentially have cured them
been detected earlier.
based on a few milliliters of blood,
of circulating tumor DNA
detection can have
for non-small cell lung cancer
which is early, is 49 percent.
at stage four, which is late,
to prevent a large number of deaths
for circulating tumor DNA
a manageable disease,
can likely be increased.
had a single chronic disease,
of the $3 trillion US health care budget
such chronic diseases.
to reduce this 86 percent,
not reacted and changed already?
is a sick care system
that focuses on prevention
in the system to change.
to shift budgets and policies
and non-financial incentives.
a regulatory framework
of personal health data
stringent and sensible.
pharmaceutical and medical companies
and, most important,
the willingness and motivation
in a sustained way,
the health data on a constant basis.
within the health care industry today
more diseases in the first place
the onset of certain preventable diseases
and healthier lives for more people.
that we need to initiate that change
ABOUT THE SPEAKER
Matthias Müllenbeck - Business developerAs the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.
Why you should listen
Throughout his career in various roles at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck worked on strategic asset, technology and diagnostic-licensing deals and on bringing to market innovative chemical products. He holds a PhD in immunology from the Humboldt University in Berlin and has worked at the Max-Planck Institute for infection biology in Berlin, at Bayer, and at the Albert-Schweizer Hospital in Lambarané, Gabon.
Matthias Müllenbeck | Speaker | TED.com